Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3

Status

Terminated 4Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 23OTHER 7NIH 2

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Melanoma 3Neoplasms 1Neoplasm Metastasis 1Leukemia, Myelomonocytic, Chronic 1Gastrointestinal Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Has results × cobimetinib × Clear all
NCT04409639 2026-04-24

CONCERTO

University of Utah

Phase 2 Active not recruiting
14 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

M.D. Anderson Cancer Center

Phase 2 Completed
49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

NCT04214418 2024-12-18

MEKiAUTO

Columbia University

Phase 1/2 Terminated
27 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
Breast

Breast Neoplasms

NCT01813214 2019-02-26

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Georgetown University

Phase 2 Terminated
5 enrolled 7 charts
Dermatologic

Melanoma

NCT01495988 2017-10-24

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma Research Foundation Breakthrough Consortium

Phase 2 Terminated
10 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡